Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Prostate Cancer

  Free Subscription


10.06.2019

1 BMC Cancer
1 BMC Urol
1 Cancer
1 Endocrinology
3 Eur J Radiol
1 Eur Radiol
9 Eur Urol
1 J Natl Cancer Inst
3 J Urol
2 N Engl J Med
1 Oncogene
1 PLoS Med
1 Proc Natl Acad Sci U S A
1 Radiology
1 Urol Int
2 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. SCHIFF JP, Cotogno P, Feibus A, Steinwald P, et al
    Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer.
    BMC Cancer. 2019;19:524.
    PubMed     Text format     Abstract available


    BMC Urol

  2. KREMER A, Kremer T, Kristiansen G, Tolkach Y, et al
    Where is the limit of prostate cancer biomarker research? Systematic investigation of potential prognostic and diagnostic biomarkers.
    BMC Urol. 2019;19:46.
    PubMed     Text format     Abstract available


    Cancer

  3. BUTLER SS, Mahal BA, Lamba N, Mossanen M, et al
    Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
    Cancer. 2019 May 31. doi: 10.1002/cncr.32202.
    PubMed     Text format     Abstract available


    Endocrinology

  4. MOON HH, Clines KL, Cooks MA, Cialek CA, et al
    Castration determines the efficacy of ETAR blockade in a mouse model of prostate cancer bone metastasis.
    Endocrinology. 2019 Jun 7. pii: 5511571. doi: 10.1210/en.2019-00261.
    PubMed     Text format     Abstract available


    Eur J Radiol

  5. DANIEL M, Polanec SH, Wengert G, Clauser P, et al
    Intra- and inter-observer variability in dependence of T1-time correction for common dynamic contrast enhanced MRI parameters in prostate cancer patients.
    Eur J Radiol. 2019;116:27-33.
    PubMed     Text format     Abstract available

  6. SCHAUDINN A, Gawlitza J, Mucha S, Linder N, et al
    Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
    Eur J Radiol. 2019;116:180-185.
    PubMed     Text format     Abstract available

  7. CUOCOLO R, Stanzione A, Ponsiglione A, Romeo V, et al
    Clinically significant prostate cancer detection on MRI: A radiomic shape features study.
    Eur J Radiol. 2019;116:144-149.
    PubMed     Text format     Abstract available


    Eur Radiol

  8. RICHENBERG J, Logager V, Panebianco V, Rouviere O, et al
    The primacy of multiparametric MRI in men with suspected prostate cancer.
    Eur Radiol. 2019 Jun 6. pii: 10.1007/s00330-019-06166.
    PubMed     Text format     Abstract available


    Eur Urol

  9. ZHOU AG, Salles DC, Samarska IV, Epstein JI, et al
    How Are Gleason Scores Categorized in the Current Literature: An Analysis and Comparison of Articles Published in 2016-2017.
    Eur Urol. 2019;75:25-31.
    PubMed     Text format     Abstract available

  10. AHMADZADEHFAR H, Essler M
    Reply to Bingzhi Wang, Huan Deng, and Lan Cao's Letter to the Editor re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi
    Eur Urol. 2019 May 28. pii: S0302-2838(19)30435.
    PubMed     Text format    

  11. BURNS JA, Weiner AB, Kundu S
    Reply to Zeynep G. Gul, Alberto Martini, and Carl A. Olsson's Letter to the Editor re: Jacob A. Burns, Adam B. Weiner, William J. Catalona, et al. Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol 2019;75:846-52.
    Eur Urol. 2019 May 28. pii: S0302-2838(19)30434.
    PubMed     Text format    

  12. MAI Z
    Re: Taimur T. Shah, Max Peters, David Eldred-Evans, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol. In press. https://doi.o
    Eur Urol. 2019 May 29. pii: S0302-2838(19)30428.
    PubMed     Text format    

  13. SHAH TT, Peters M, Arya M, Ahmed HU, et al
    Reply to Zhipeng Mai's Letter to the Editor re: Taimur T. Shah, Max Peters, David Eldred-Evans, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre
    Eur Urol. 2019 May 29. pii: S0302-2838(19)30427.
    PubMed     Text format    

  14. GUL ZG, Martini A, Olsson CA
    Re: Jacob A. Burns, Adam B. Weiner, William J. Catalone, et al. Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol 2019;75:846-52.
    Eur Urol. 2019 Jun 1. pii: S0302-2838(19)30433.
    PubMed     Text format    

  15. VAN DER LEEST M, Israel B, Cornel EB, Zamecnik P, et al
    High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naive Men: The Next Step in Magnetic Resonance Imaging Accessibility.
    Eur Urol. 2019 Jun 2. pii: S0302-2838(19)30436.
    PubMed     Text format     Abstract available

  16. WYATT AW, Chi KN, Gleave ME
    Reply to Rodolfo Montironi, Liang Cheng, Marina Scarpelli, Alessia Cimadamore, Francesco Montorsi, and Antonio Lopez-Beltran's Letter to the Editor re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and P
    Eur Urol. 2019 Jun 2. pii: S0302-2838(19)30443.
    PubMed     Text format    

  17. ROCCO B, Sighinolfi MC
    Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:285-93.
    Eur Urol. 2019 May 29. pii: S0302-2838(19)30437.
    PubMed     Text format    


    J Natl Cancer Inst

  18. JEON J, Olkhov-Mitsel E, Xie H, Yao CQ, et al
    Temporal stability and prognostic biomarker potential of the prostate cancer urine transcriptome.
    J Natl Cancer Inst. 2019 Jun 4. pii: 5510559. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Urol

  19. SIEGEL C
    Re: A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI.
    J Urol. 2019 Jun 5:101097JU0000000000000371. doi: 10.1097/JU.0000000000000371.
    PubMed     Text format    

  20. SHAH N, Ioffe V
    Re: Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. Keyan Salari et al. JOU. Vol 201, 721-727, April 2019.
    J Urol. 2019 Jun 4:101097JU0000000000000362. doi: 10.1097/JU.0000000000000362.
    PubMed     Text format    

  21. SALARI K, Feldman AS
    Re: Salari et al. Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. JUrol. Vol 201, 721-727, April 2019.
    J Urol. 2019 Jun 4:101097JU0000000000000363. doi: 10.1097/JU.0000000000000363.
    PubMed     Text format    


    N Engl J Med

  22. CHI KN, Agarwal N, Bjartell A, Chung BH, et al
    Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    N Engl J Med. 2019 May 31. doi: 10.1056/NEJMoa1903307.
    PubMed     Text format     Abstract available

  23. DAVIS ID, Martin AJ, Stockler MR, Begbie S, et al
    Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
    N Engl J Med. 2019 Jun 2. doi: 10.1056/NEJMoa1903835.
    PubMed     Text format     Abstract available


    Oncogene

  24. LEE CF, Dang A, Hernandez E, Pong RC, et al
    Activation of sphingosine kinase by lipopolysaccharide promotes prostate cancer cell invasion and metastasis via SphK1/S1PR4/matriptase.
    Oncogene. 2019 May 31. pii: 10.1038/s41388-019-0833.
    PubMed     Text format     Abstract available


    PLoS Med

  25. JAMBOR I, Verho J, Ettala O, Knaapila J, et al
    Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial.
    PLoS Med. 2019;16:e1002813.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  26. PRADHAN AK, Bhoopathi P, Talukdar S, Scheunemann D, et al
    MDA-7/IL-24 regulates the miRNA processing enzyme DICER through downregulation of MITF.
    Proc Natl Acad Sci U S A. 2019;116:5687-5692.
    PubMed     Text format     Abstract available


    Radiology

  27. COLLETTINI F, Enders J, Stephan C, Fischer T, et al
    Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes.
    Radiology. 2019 Jun 4:181987. doi: 10.1148/radiol.2019181987.
    PubMed     Text format     Abstract available


    Urol Int

  28. PORCARO AB, Tafuri A, Sebben M, Pirozzi M, et al
    Positive Association between Basal Total Testosterone Circulating Levels and Tumor Grade Groups at the Time of Diagnosis of Prostate Cancer.
    Urol Int. 2019 Jun 4:1-8. doi: 10.1159/000500960.
    PubMed     Text format     Abstract available


    Urology

  29. GEJERMAN G
    Editorial Comment.
    Urology. 2019;126:151.
    PubMed     Text format    

  30. SINGHAL U, Morgan TM, Tosoian JJ
    EDITORIAL COMMENT.
    Urology. 2019;126:82.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: